Eton Pharmaceuticals, Inc. (ETON) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ETON Revenue Growth
Revenue Breakdown (FY 2025)
ETON's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ETON Revenue Analysis (2017–2025)
As of May 8, 2026, Eton Pharmaceuticals, Inc. (ETON) generated trailing twelve-month (TTM) revenue of $80.0 million, reflecting explosive growth of +82.7% year-over-year. The most recent quarter (Q4 2025) recorded $21.3 million in revenue, down 5.2% sequentially.
Looking at the longer-term picture, ETON's 5-year compound annual growth rate (CAGR) stands at +359.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $80.0 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ETON's business is primarily driven by Product Sales and Royalties (96%), and License (4%). With over half of revenue concentrated in Product Sales and Royalties, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AVDL (+79.9% YoY), and TLRY (+3.0% YoY), ETON has outperformed the peer group in terms of revenue growth. Compare ETON vs AVDL →
ETON Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ETONCurrent | $80M | +82.7% | +359.6% | -1.1% | |
 AVDL | $169M | +79.9% | +23.4% | -25.1% | |
 TLRY | $1.1B | +3.0% | +22.7% | -277.9% |
ETON Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $80.0M | +104.9% | $42.7M | 53.5% | $-844,000 | -1.1% |
| 2024 | $39.0M | +23.3% | $23.4M | 60.0% | $-2,597,000 | -6.7% |
| 2023 | $31.6M | +48.9% | $21.1M | 66.6% | $-1,192,000 | -3.8% |
| 2022 | $21.3M | -2.7% | $14.3M | 67.4% | $-8,260,000 | -38.9% |
| 2021 | $21.8M | +55879.5% | $19.2M | 88.0% | $-1,495,000 | -6.8% |
| 2020 | $39K | -95.9% | $-247,000 | -633.3% | $-27,111,000 | -69515.4% |
| 2019 | $959K | - | $506K | 52.8% | $-18,601,000 | -1939.6% |
| 2018 | $0 | - | $-63,000 | - | $-10,321,000 | - |
| 2017 | $0 | - | $-13,000 | - | $-7,150,000 | - |
See ETON's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ETON Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ETON vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonETON — Frequently Asked Questions
Quick answers to the most common questions about buying ETON stock.
Is ETON's revenue growth accelerating or slowing?
ETON revenue is accelerating at +82.7% year-over-year, exceeding the 5-year CAGR of +359.6%. TTM revenue reached $80M. Growth momentum has increased versus prior periods.
What is ETON's long-term revenue growth rate?
Eton Pharmaceuticals, Inc.'s 5-year revenue CAGR of +359.6% reflects the sustained expansion pattern. Current YoY growth of +82.7% is above this long-term average.
How is ETON's revenue distributed by segment?
ETON reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.